Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KNP-101
- Development stage
- Preclinical
- Lead developer
- Kanaph Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KNP-101 is a bi-specific immunocytokine designed for cancer immunotherapy, particularly targeting solid tumors. It consists of an engineered interleukin-12 (IL-12) mutant arm with attenuated activity to reduce toxicity, fused to an antibody that targets fibroblast activation protein (FAP), which is highly expressed in the tumor microenvironment (TME) of many solid tumors. This dual approach aims to deliver IL-12 selectively to the TME, enhancing anti-tumor immune responses while minimizing systemic side effects. The drug is being developed as a next-generation therapy for use alone or in combination with checkpoint inhibitors, especially in non-small cell lung cancer (NSCLC) and other FAP-expressing solid tumors. Its current development stage is preclinical[1][2][7].
- Other names
- DA-3101DA3101DA 3101
02
Targets
IL-12R (Interleukin-12 receptor)FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on KNP-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KNP-101.